No 01 2023

IDRx is a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of GIST.

Rappta Therapeutics has announced an exclusive global license agreement with SpringWorks Therapeutics for RPT04402, a first-in-class molecular glue of specific Protein Phosphatase 2A (PP2A) complexes. 

The Research Council of Norway has granted NOK 50 million to the Oslo University Hospital (OUH), in partnership with the University of Oslo and the Haukeland University Hospital (HUH) for the development and distribution of ATMPs, reports Sofia Lindén/Oslo Cancer Cluster (OCC).

ALK has announced that its European regulatory filing for ACARIZAX (house dust mite sublingual allergy immunotherapy tablet) in young children aged five to 11 has been approved by the health authorities in 21 EU countries via a type II variation procedure.

Mikko Kemppainen has been appointed as General Counsel and Secretary to the Board of Directors of Orion Corporation, and a member of the Executive Management Board of the Orion Group as of 1 June 2025.

The Board of Directors of Arjo and Joacim Lindoff have come to an agreement which implicates Joacim leaving his position as President & CEO of Arjo, a role he has held since 2017.

ReciBioPharm, a division of Recipharm, has been awarded a three-year grant from the Bill & Melinda Gates Foundation.